In the last few days, there have been two studies on Taxotere (docetaxel) for breast cancer. Links to these and other studies may be found on the Taxotere (docetaxel) page of the LATESTBreastCancer.com website.
Taxotere, Navelbine and Herceptin for Metastatic Breast Cancer
According to an August 9 Breast Cancer Research and Treatment phase II study, "The combination of trastuzumab, docetaxel, and vinorelbine is effective as first-line chemotherapy in HER2-positive MBC [metastatic breast cancer] with minimal toxicity. One-year survival estimates are among the highest reported in this population."
Androgen receptor status and response to Taxotere
A pathological complete response (pCR) occurs when a tumor disappears after treatment. Studies often evaluate how different factors, such as estrogen or progesterone receptor status affect pCR in response to treatment.
An August 12 study from Germany in Breast Cancer Research and Treatment considered the effect of androgen receptor status on pCR and overall survival in patients treated with Taxotere/Adriamycin/Cytoxan (TAC) chemotherapy before surgery (neoadjuvant). Patients with androgen receptor (AR) positive tumors had a lower chance of achieving pCR than patients with AR negative tumors, but "better survival, especially if they did not achieve a pCR."
Additional research, news, general information and FDA product information on Taxotere may be found on the LATESTBreastCancer.com website. We update our website and database daily.